Gabather

0.148

SEK

-9.79 %

GABA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Less than 1K followers

-9.79%

-63.13%

-58.91%

-74.91%

-79.28%

-85.82%

-96.67%

-97.45%

-99.07%

Gabather is a pharmaceutical company. Today, there is a business focus on developing drug candidates for the treatment of nerve diseases. Particular focus is on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are today patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.

Market cap

3.5M SEK

Turnover

36.75K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Financial calendar

21.2

2025

Extraordinary general meeting '25

27.2

2025

Annual report '24

28.5

2025

Interim report Q1'25

ShowingAll content types

Regulatory press release1/13/2025, 7:30 AM

Gabather AB appoints Pareto Securities AB to act as a liquidity provider for the Company's share

Regulatory press release4/10/2024, 11:00 AM

Gabather AB: Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002

Press release3/18/2024, 7:30 AM

Gabather AB: Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release3/7/2024, 8:02 AM

Gabather AB: Gabather reports initial positive results from the EEG/fMRI target engagement study

Regulatory press release12/22/2023, 2:03 PM

Gabather AB receives initial EEG data analysis from the GT-002 target engagement study

Regulatory press release12/14/2023, 8:16 AM

Gabather AB initiates discussions with specialist doctors and researchers at Karolinska Institutet for the design of a study in individuals at risk of developing frontotemporal dementia (FTD)

Regulatory press release12/11/2023, 12:23 PM

Gabather AB broadens the scope of EEG data analysis generated during the target engagement study by partnering with MINDIG

Regulatory press release10/12/2023, 12:00 PM

Gabather AB: Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers

Regulatory press release4/13/2023, 6:45 AM

Gabather AB: Gabather, Receives Notice of Approval from the Japanese Patent Office (JPO) for its National Phase Application No. 2020-554957

Regulatory press release6/7/2022, 8:57 AM

Gabather AB, receives Notice of Allowance from the U.S. Patent Office for its U.S. patent application publication No. US 2021/0087193 A1

Press release6/2/2022, 8:00 AM

Gabather AB: BioStock: Gabather's lead candidate moves forward in the clinic

Regulatory press release5/17/2022, 1:36 PM

Gabather AB: Gabather receives approval to start the EEG/fMRI target engagement study with the drug candidate GT-002

Regulatory press release3/22/2022, 8:00 AM

Gabather AB invited by the Alzheimer's Drug Discovery Foundation, USA to submit a grant application to expand the studies with GT-002 in preclinical models of Alzheimer's disease

Regulatory press release9/14/2021, 6:37 AM

Gabather AB: BioStock: Gabather poised to complete phase I with GT-002

Regulatory press release5/10/2021, 8:19 AM

Gabather AB: BioStock: Covid unmasks need for better mental health medication

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.